MSAC publishes agenda for upcoming meeting

3 September 2021 - 12 agenda items for consideration at the 25-26 November 2021 meeting. ...

Read more →

Pillar Biosciences receives premarket approval from FDA for its oncoReveal Dx lung and colon cancer assay

5 August 2021 - Pillar Biosciences today announced the U.S. FDA has given premarket approval to its oncoReveal Dx Lung ...

Read more →

Foundation Medicine expands indication for FoundationOne Liquid CDx to be used as a companion diagnostic for Tabrecta (capmatinib)

15 July 2021 - Tabrecta is the first FDA approved MET inhibitor for patients with metastatic non-small cell lung cancer with ...

Read more →

Sonic Healthcare USA to offer assay to aid in the selection of Jemperli (dostarlimab-gxly) therapy in endometrial cancer

2 July 2021 - LMC Pathology Services, a Sonic Healthcare USA Anatomic Pathology Practice, is the first reference laboratory in ...

Read more →

FoundationOne CDx receives FDA approval as a companion diagnostic for Alunbrig (brigatinib) to identify patients with ALK positive metastatic non-small cell lung cancer

1 July 2021 - Foundation Medicine today announced that it has received approval from the U.S. FDA for FoundationOne CDx to ...

Read more →

New cancer gene test: are you eligible?

29 June 2021 - In a world first, young Australians will be offered a genetic test to discover whether they carry ...

Read more →

Lantheus receives U.S. FDA approval of Pylarify (piflufolastat F 18) injection, the first and only commercially available PSMA PET imaging agent for prostate cancer

27 May 2021 - Pylarify will be available immediately to imaging centres in parts of the mid-Atlantic and southern regions and ...

Read more →

Illuminare-1, a novel nerve visualisation investigational fluorophore, granted fast track designation by U.S. FDA

25 May 2021 - Illuminare Biotechnologies announced that its novel nerve imaging agent, Illuminare-1, has been granted fast track designation by ...

Read more →

Alume Biosciences granted FDA fast track designation of ALM-488 for surgical nerve visualisation

12 May 2021 - Fast track designation highlights the urgent need for improved intra-operative nerve identification. ...

Read more →

Viome receives FDA approval for its unique mRNA technology and AI platform to detect cancers

6 May 2021 - FDA breakthrough designation validates Viome's proprietary mRNA analysing technology and state of the art AI platform to ...

Read more →

Australia's TGA grants approval to first objective concussion diagnostic

4 May 2021 - Oculogica's EyeBOX is the only objective diagnostic cleared by the US FDA and Australia TGA as an ...

Read more →

Cancer deaths could be reduced with genomic testing investment, says National Oncology Alliance

26 April 2021 - Half of the more than 550,000 Australians expected to die from cancer in the next decade could ...

Read more →

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy

23 April 2021 - VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the ...

Read more →

Amgen launches Biomarker Assist, a program to help more patients with non-small cell lung cancer gain access to biomarker testing

19 April 2021 - Half of all patients with non-small cell lung cancer have oncogene mutations, yet many patients are not ...

Read more →

Biocartis announces US FDA 510(k) submission of its Idylla MSI test

20 April 2021 - First US FDA oncology assay submission for Biocartis. ...

Read more →